New Delhi: India’s first indigenously developed Covid-19 vaccine–COVAXIN has been started screening for children, aged between 2 and 18.
The screening of children for the trial of the vaccine started at the AIIMS in Delhi on Monday.
Until now, AIIMS Patna has started the Paediatric clinical trial of the Covaxin after Bharat Biotech received the Drugs Controller General of India (DCGI) nod to conduct clinical trials on children on May 11.
According to AIIMS officials, the trial will be conducted on 525 healthy volunteers and the vaccine will be given by intramuscular route in two doses at day 0 and day 28. Participants would be given the vaccine after their screening report comes.
Reportedly, COVAXIN is being used on adults in India’s ongoing Covid-19 vaccination drive and India’s drug regulator had granted permission for conducting the Phase 2/3 clinical trial of COVAXIN in the age group 2 to 18 years on May 12.
Comments are closed.